/CODX
CODX Stock - Co-Diagnostics, Inc.
Healthcare|Medical - DevicesNASDAQ
$0.26-4.35%
$0.01 (-4.35%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.14
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+3310.4%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CODX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.26 – $0.27
TARGET (TP)$9.00
STOP LOSS$0.24
RISK/REWARD1:365.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.16
52W High$1.55
52W Low$0.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.92M | $6.81M | $34.22M | $97.89M | $74.55M |
| Gross Profit | $2.92M | $2.63M | $28.74M | $86.31M | $57.96M |
| Gross Margin | 74.5% | 38.6% | 84.0% | 88.2% | 77.7% |
| Operating Income | $-40,081,310 | $-42,706,234 | $-26,979,837 | $46.06M | $41.69M |
| Net Income | $-37,639,008 | $-35,332,865 | $-14,238,249 | $36.66M | $42.48M |
| Net Margin | -961.4% | -518.7% | -41.6% | 37.5% | 57.0% |
| EPS | $-1.24 | $-1.20 | $-0.45 | $1.27 | $1.59 |
Company Overview
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
1
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish1 Neutral/Bearish
Price Targets
$5
Average Target
↑ 1794.7% Upside
Now
$5
Low
$5
Average
$5
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 12th 2022 | Sidoti | Downgrade | Neutral | $5 |
Earnings History & Surprises
CODXBeat Rate
68%
Last 19 quarters
Avg Surprise
-2.8%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
-150.0%
$-0.50vs$-0.20
Q2 24
-47.6%
$-0.31vs$-0.21
Q3 24
+26.5%
$-0.25vs$-0.34
Q4 24
+3.0%
$-0.32vs$-0.33
Q1 25
-5.9%
$-0.36vs$-0.34
Q2 25
+27.3%
$-0.24vs$-0.33
Q3 25
+8.0%
$-0.23vs$-0.25
Q4 25
+15.8%
$-0.16vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.33 | $-0.24 | +27.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.33 | $-0.32 | +3.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.21 | $-0.31 | -47.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.20 | $-0.50 | -150.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.29 | $-0.20 | +31.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.24 | $-0.31 | -29.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.15 | $-0.32 | -113.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $0.15 | $-0.10 | -166.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $0.18 | $0.26 | +44.4% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $0.12 | $0.25 | +108.3% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $0.21 | $0.38 | +81.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $0.22 | $0.33 | +50.0% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $0.22 | $0.26 | +18.2% | ✓ BEAT |
Latest News
Co-Diagnostics Says Co Performs Analysis Of Influenza Co-Primers To Confirm Reactivity Against Flu A H3N2 Mutation
➖ NeutralBenzinga•Dec 17, 2025, 02:01 PM
HC Wainwright & Co. Reiterates Neutral on Co-Diagnosticsto Neutral
➖ NeutralBenzinga•Nov 24, 2025, 12:31 PM
Co-Diagnostics Initiates Clinical Evaluations for Its Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit
📈 PositiveBenzinga•Nov 18, 2025, 02:04 PM
Co-Diagnostics Q3 EPS $(0.16) Beats $(0.17) Estimate, Sales $145.380K Miss $150.000K Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:02 PM
Co-Diagnostics Engages Maxim Group To Explore Strategic Options For Indian Joint Venture CoSara, Including Potential SPAC Merger
📈 PositiveBenzinga•Nov 5, 2025, 02:08 PM
Co-Diagnostics Forms New Artificial Intelligence Business Unit To Integrate Its Current, Planned AI Applications Into Co-Dx Primer Ai
📈 PositiveBenzinga•Nov 3, 2025, 02:18 PM
Co-Diagnostics Files For Offering 12M Shares Of Common Stock And 725,000 Pre-Funded Warrants
📉 NegativeBenzinga•Oct 28, 2025, 09:45 PM
Co-Diagnostics shares are trading lower after the company announced a $7 million registered direct offering of 12,727,272 shares at $0.55 per share.
📉 NegativeBenzinga•Oct 28, 2025, 03:59 PM
Co-Diagnostics Announces $7M Registered Direct Offering Of 12,727,272 Shares At A Price Of $0.55/Share
📉 NegativeBenzinga•Oct 28, 2025, 01:35 PM
D. Boral Capital Maintains Buy on Co-Diagnostics, Maintains $3 Price Target
📈 PositiveBenzinga•Oct 28, 2025, 11:09 AM
Co-Diagnostics Shares Resume Trade
➖ NeutralBenzinga•Oct 27, 2025, 06:26 PM
Co-Diagnostics shares are trading higher after the company signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics and localize its Co-Dx PCR platform across the Middle East.
📈 PositiveBenzinga•Oct 27, 2025, 12:47 PM
EXCLUSIVE: Co-Diagnostics Tells Benzinga 'The new Saudi-based CoMira Diagnostics joint venture will be engaged in manufacturing and distribution of the Company's upcoming Co-Dx PCR platform and other Co-Dx IP across KSA and 18 other MENA countries'
📈 PositiveBenzinga•Oct 27, 2025, 12:30 PM
EXCLUSIVE: Co-Diagnostics Tells Benzinga Co. Co-Diagnostics Signs Definitive Agreement With Arabian Eagle In The Kingdom of Saudi Arabia To Establish CoMira Diagnostics And Localize Co-Dx PCR Platform Across The Middle East
📈 PositiveBenzinga•Oct 27, 2025, 12:30 PM
Co-Diagnostics Enters Equity Distribution Agreement With Maxim Group; May Sell Common Stock Up To $10M From Time To Time
➖ NeutralBenzinga•Oct 20, 2025, 01:57 PM
D. Boral Capital Maintains Buy on Co-Diagnostics, Maintains $3 Price Target
📈 PositiveBenzinga•Oct 16, 2025, 07:19 PM
Co-Diagnostics Develops Proprietary Sample Preparation Instrument Designed To Streamline And Simplify Workflow For PoC Co-Dx PCR Mycobacterium Tuberculosis Test
📈 PositiveBenzinga•Oct 16, 2025, 01:34 PM
D. Boral Capital Maintains Buy on Co-Diagnostics, Lowers Price Target to $3
➖ NeutralBenzinga•Sep 19, 2025, 11:18 AM
Co-Diagnostics shares are trading lower after the company announced a $3.8 million registered direct offering of 9.619 million shares at a price of $0.40 per share.
📉 NegativeBenzinga•Sep 17, 2025, 03:15 PM
Co-Diagnostics Announces $3.8M Registered Direct Offering Of 9.619M Shares At A Price Of $0.40/Share
📉 NegativeBenzinga•Sep 17, 2025, 01:48 PM
Frequently Asked Questions about CODX
What is CODX's current stock price?
Co-Diagnostics, Inc. (CODX) is currently trading at $0.26 per share. The stock has moved -4.35% today.
What is the analyst price target for CODX?
The average analyst price target for CODX is $9.00, based on 1 analyst.
What sector is Co-Diagnostics, Inc. in?
Co-Diagnostics, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is CODX's market cap?
Co-Diagnostics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does CODX pay dividends?
No, Co-Diagnostics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADGM
Adagio Medical Holdings, Inc.
$1.03
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.86
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.47
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
NVNO
enVVeno Medical Corporation
$0.32
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.09
Mkt Cap: $0.0B
SINT
Sintx Technologies, Inc.
$3.61
Mkt Cap: $0.0B
TNON
Tenon Medical, Inc.
$1.10
Mkt Cap: $0.0B
VVOS
Vivos Therapeutics, Inc.
$1.97
Mkt Cap: $0.0B
XAIR
Beyond Air, Inc.
$0.91
Mkt Cap: $0.0B
Explore stocks similar to CODX for comparison